ArticleGastroenterology research2025
Clinicopathological Features of KRAS-Mutated Colon Cancer: An Analytical Cross-Sectional Study.
Article in Gastroenterology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between KRAS gene mutation and clinicopathological factors in patients with metastatic colorectal cancer.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colon cancer is a leading neoplasm worldwide, with 35% to 45% of colorectal cancer (CRC) patients exhibiting mutations in the Kirsten rat sarcoma oncogene ( Methods: An analytical cross-sectional study involving patients with CRC was conducted. The study variables included sex, age, tumor location, Results: The study involved 51 patients, with a mean (standard deviation) age of 61.4 ± 11.0 years. The most common tumor location was the sigmoid colon (35.3%), and 45.1% of patients were classified as tumor, node, metastasis (TNM) stage III with lymph node dissemination. Genetic analysis revealed that 35% of patients had Conclusions: KRAS-positive patients predominantly had tumors in the sigmoid colon. The coexistence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.